Kevin Kelly, MD 2017-04-19T14:10:36+00:00


Back to Index
Kevin Kelly, MD
Associate Professor of Clinical Medicine
NOR 1441 Eastlake Ave Health Sciences Campus Los Angeles
+1 323 865 3828


Dr. Kelly is a hematologist with clinical expertise in phase I investigational therapeutics and hematological malignancies, including lymphoma and multiple myeloma. His research focuses on understanding the mechanisms of resistance to chemotherapy in hematological malignancies and the use of novel agents to overcome this resistance, and he has published extensively in peer-reviewed journals. Through collaborations with a large team of scientists, he has translated preclinical discoveries into novel clinical trials including an investigator-initiated study of the phosphodiesterase 4B inhibitor, roflumilast, in B cell lymphoproliferative disorders.

Dr. Kelly earned his medical degree and PhD from University College Cork. He then went on to complete an Advanced Drug Development Clinical Fellowship at The University of Texas Health Science Center.


EORTC-NCI-ASCO Annual Meeting on Molecular Markers in Cancer: Travel Award, 2011

ASCO/AACR Workshop on Methods in Clinical Cancer Research: Travel Award, 2009

National Cancer Institute: Cancer Clinical Investigator Team Leadership Award, 2016


Kelly K, Mejia A, Suhasini AN, Lin AP, Kuhn J, Karnad AB, Weitman S, Aguiar RC. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. Clin Cancer Res. 2017 Mar 01; 23(5):1186-1192. View in: PubMed

Kelly KR, Gabrail N, Weitman S, Sarantopoulos J, Olszanski AJ, Edenfield W, Venitz J, Reddy G, Yang A, Hasal SJ, Lockhart AC. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemother Pharmacol. 2016 Nov; 78(5):929-939. View in: PubMed

Siddiqi IN, Friedman J, Barry-Holson KQ, Ma C, Thodima V, Kang I, Padmanabhan R, Dias LM, Kelly KR, Brynes RK, Kamalakaran S, Houldsworth J. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol. 2016 Jun; 29(6):570-81. View in: PubMed

Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016 May; 17(5):622-31. View in: PubMed

Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45. View in: PubMed

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 1; 22(1):34-43. View in: PubMed

Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 1; 6(38):41275-89. View in: PubMed

Nawrocki ST, Kelly KR, Smith PG, Keaton M, Carraway H, Sekeres MA, Maciejewski JP, Carew JS. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine. Clin Cancer Res. 2015 Jan 15; 21(2):439-47. View in: PubMed

Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014 Nov; 167(3):366-75. View in: PubMed

Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014 Jun; 32(3):489-99. View in: PubMed

Laille E, Goel S, Mita AC, Gabrail NY, Kelly K, Liu L, Songer S, Beach CL. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Pharmacotherapy. 2014 May; 34(5):440-51. View in: PubMed

Merin NM, Kelly KR. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel). 2014; 8(1):1-20. View in: PubMed

Rowe J, Patel S, Mazo-Canola M, Parra A, Goros M, Michalek J, Kelly K, Weitman S, Karnad A. An evaluation of elderly patients (=70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011. J Geriatr Oncol. 2014 Jan; 5(1):65-70. View in: PubMed

Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, Carew JS. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 2013 Jul 1; 19(13):3577-90. View in: PubMed

Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, Ecsedy J, Giles FJ, Carew JS. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer. 2012 Dec 1; 131(11):2693-703. View in: PubMed

Nawrocki ST, Griffin P, Kelly KR, Carew JS. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012 Oct; 21(10):1563-73. View in: PubMed

Carew JS, Kelly KR, Nawrocki ST. Autophagy as a target for cancer therapy: new developments. Cancer Manag Res. 2012; 4:357-65. View in: PubMed

Kelly KR, Espitia CM, Taverna P, Choy G, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol. 2012 Jan; 156(1):129-32. View in: PubMed

Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS. Targeting aurora kinases in cancer treatment. Curr Drug Targets. 2011 Dec; 12(14):2067-78. View in: PubMed

Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. The Pim kinases: new targets for drug development. Curr Drug Targets. 2011 Dec; 12(14):2059-66. View in: PubMed

Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011 Oct; 15(10):2057-70. View in: PubMed

Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011 Mar; 6(1):53-61. View in: PubMed

Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011 Mar; 6(1):17-27. View in: PubMed

Carew JS, Espitia CM, Esquivel JA, Mahalingam D, Kelly KR, Reddy G, Giles FJ, Nawrocki ST. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25; 286(8):6602-13. View in: PubMed

Carew JS, Medina EC, Esquivel JA, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2010 Oct; 14(10):2448-59. View in: PubMed

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010 May 6; 115(18):3796-800. View in: PubMed

Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. Cdc7 kinase - a new target for drug development. Eur J Cancer. 2010 Jan; 46(1):33-40. View in: PubMed

Mahalingam D, Medina EC, Esquivel JA, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010 Jan 1; 16(1):141-53. View in: PubMed

Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Reovirus-based therapy for cancer. Expert Opin Biol Ther. 2009 Jul; 9(7):817-30. View in: PubMed

Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs. 2009 Jun; 14(2):311-28. View in: PubMed

Powered bySC CTSI